Islet encapsulation: advances and obstacles
- G. C. WeirAffiliated withSection on Islet Cell Biology and Regenerative Medicine, Joslin Diabetes CenterDepartment of Medicine, Harvard Medical School Email author
It has been known for decades that encapsulation can protect transplanted islets from immune destruction in rodents, but it has proved difficult to extend this success to large animals and humans. A new study in this issue by Jacobs-Tulleneers-Thevissen et al (doi: 10.1007/s00125-013-2906-0) advances the field by showing that human islets contained in alginate capsules can function very well, not only in the peritoneal cavity of mice, but also in a human with type 1 diabetes. Many obstacles must still be overcome, but this technology has the potential to safely protect transplanted beta cells from autoimmunity and allorejection.
KeywordsBeta cell Biomaterials Diabetes Encapsulation Insulin secretion Islets
The paper by Jacobs-Tulleneers-Thevissen and co-workers in this issue  presents an advance in the re-energised field of islet encapsulation, which is a strategy to protect transplanted beta cells from immune destruction. The demonstration in 1989  that the diabetic state can be reversed in humans by cellular transplantation provided an important proof-of-principle demonstration reinforcing the concept that the goal of beta cell replacement is a major priority for diabetes research. This potential is most obvious for type 1 diabetes, where even partial replenishment of near complete beta cell deficiency with isolated islets transplanted into the liver via the portal vein can normalise blood glucose levels. Similar treatment approaches for type 2 diabetes are less often considered, but beta cell mass is generally reduced by 40–60% , and normoglycaemia can be restored with whole pancreas transplantation providing beta cell replacement .
The simplicity of the concept of beta cell replacement has created high expectations, but decades of intense work have been hindered by two obstacles: (1) the lack of an adequate supply of islet cells and (2) the absence of a means of protecting them from destruction by autoimmunity and allorejection. The quest to find a new source of beta cells has brought about impressive advances in unlocking the potential of stem cells and finding ways to exploit the possibility of islet cell regeneration.
Finding strategies to curb immune destruction has proved to be particularly daunting. The loss of tolerance in autoimmunity and the components of allorejection are now certainly better understood, but they are vicious complex processes that have proved difficult to control. Something better than the blunt instrument of current immunosuppression is needed. The frustration of not being able to identify a safe way to tame the immune system has sparked renewed interest in providing protection by encapsulation.
Why work on encapsulation?
The possibility that semi-permeable membranes can protect islet cells has attracted attention since the 1970s, yet a great deal of work by a variety of academic scientists and industry has only resulted in variable success in rodents and little that is encouraging in large animals and humans . The principle is that the islet cells are encapsulated using a membrane porous enough to allow passage of glucose, oxygen, nutrients and insulin, but restrictive enough to keep out immune cells and some potentially toxic cytokines, antibodies and complement proteins. The two main approaches are macro- and microencapsulation. Most macrodevices are flat thin rectangular containers made of various materials that can contain large numbers of islets. These might be implanted in subcutaneous or intra-abdominal sites, or even under the kidney capsule. Microcapsules typically contain just a few islets worth of cells within a hydrogel bead, most commonly consisting of alginate obtained from seaweed [6, 7]. Islets can also be individually covered with a tight-fitting conformal coating, typically consisting of polyethylene glycol (PEG) .
Recent progress in islet encapsulation: advances and clarification of problems
The study by Jacobs-Tulleneers-Thevissen and co-workers in this issue  advances the field of islet encapsulation with two main findings. The first is that transplanted encapsulated human islet cells contained in alginate microcapsules placed in the peritoneal cavity can survive and reverse diabetes very well in mice, considerably better than comparable ‘free implants’ (non-encapsulated cells) transplanted under the kidney capsule. Following retrieval from the peritoneal cavity after 5 weeks, the beta cells in the capsules were found to have healthy insulin secretory responses to both glucose and glucagon stimulation, and their unique secretory granules could be identified by electron microscopy. Interestingly, the cell composition of cells in the capsules changed over the 5-week period. When initially encapsulated the population contained a lot of duct cells, as is typical for a human islet preparation (42% beta cells, 12% alpha cells and 41% duct cells), but after 5 weeks the proportion of duct cells was considerably diminished (54% beta cells, 18% alpha cells and 20% duct cells). The explanation for this changed ratio is unclear, but probably results from differing rates of birth and death between islet and duct cells. Another intriguing possibility is that some duct cells differentiated into islet cells through the process of neogenesis . These results suggest that microencapsulated human islets cells should also do well when transplanted into humans.
The second major finding resulted from placing microencapsulated human islets into the peritoneal cavity of an individual with type 1 diabetes, who had a failed intraportal islet graft but was still on immunosuppressive therapy. The islet dose was subtherapeutic and had no measurable metabolic impact, but it allowed the first detailed look at islet-containing alginate microcapsules retrieved 3 months after transplantation in humans. The most encouraging findings were that some of the capsules were free floating without fibrosis and contained healthy beta cells that showed insulin secretory responses to stimulation by glucose, but, for unclear reasons, not by glucagon. Other good news is that the patient reported no abdominal discomfort or other symptoms following the transplant; this was also the case in two other reports of humans with transplanted encapsulated human islets [10, 11]. Taken together, these findings in mice and the pilot study with a human participant show that microencapsulated human islet cells can do well when transplanted into the peritoneal cavity.
Clarification of problems
These studies also highlight some of the serious problems facing the field. Microcapsules containing islet cells and even ‘empty capsules’ without any cells can elicit an inflammatory reaction that covers the capsule surface and evolves to fibrosis. Islets inside fare badly, presumably mainly because of suffocation as a result of competition for oxygen from the inflammatory cells. These reactions are poorly understood but are likely to be due to some combination of reactivity of the biomaterials, the genetic background of the recipients, and the immune reaction to antigens and cytokines released by the contained cells. Xenografts do worse than allografts, and unhealthy cells are also more likely to have poor outcomes. An important consideration is that the immunosuppression provided for the patient in this study could have suppressed a reaction to the capsule.
The islet cells of the future
Human islet preparations come from cadaver pancreases and are therefore in short supply; they also typically contain many dead and dying cells and are contaminated with exocrine cells. They help advance research, but the prospect of using islet cells generated from pluripotent stem cells or other islet precursors in the future seems more promising [13, 14]. Porcine islet cells could also suffice before an abundant human source is identified. An interesting unanswered question is whether beta cells alone could provide adequate secretion or whether they must be accompanied by islet non-beta cells. Also, theory and some experimental data suggest that small aggregates of healthy islet cells with a diameter of 30–60 μm will function better than those that are islet-sized with a diameter of more than 150 μm . Another unresolved question is how long encapsulated human islet cells can survive and function in a transplant site. There is some evidence that they can survive for many months and even years [6, 16], but practical questions remain about the survival kinetics of islet cells and how often they will need to be replenished.
The need for more reliable biomaterials
The most widely used material for microencapsulation is the hydrogel alginate, of which there are a variety of types, and cross-linking to form a gel can be provided by several cations. The gel bead can be coated with a polycation such as poly-l-lysine to add strength and provide more permselectivity. In addition, there are a variety of capsule sizes and configurations, including double core/shell versions. However, a major shortcoming of the field is that there are as yet no standardised formulations that can provide reproducible results in different laboratories.
How much permselectivity is required?
While it is clear that immune cells must be separated from the islet cells, questions can be raised about the need to keep out cytokines, antibodies and complement proteins, or to limit the release of antigens. We know that high concentrations of cytokines can kill islet cells, but it has never been shown that these toxic levels are ever reached within capsules. There is some evidence in rodents that encapsulated xenogeneic tissue is more vulnerable than allogenic tissue and it is generally thought that tighter membranes provide better survival. Although it is logical to assume that release of xenoantigens is the culprit, we have little understanding of even which antigens are responsible.
Will the kinetics of insulin release be adequate?
Secreted insulin from richly vascularised islets in the pancreas is rapidly delivered to blood such that insulin levels can rise quickly and fall in a just few minutes when secretion is shut off by declining glucose levels. Very little is known about the kinetics of insulin release from encapsulated islets, but because insulin must diffuse various distances before reaching the circulation, there may be problems obtaining timely release for meals and shutting insulin off after meals or during exercise. As depicted in Fig. 1, insulin release kinetics will be even more problematic when microcapsules are clumped.
The packing density issue
This question focuses on oxygen supply and how much biomaterial is required to protect a given mass of islet cells. This becomes a major concern for current plans to transplant macroencapsulated islet precursor cells derived from pluripotent stem cells, which can develop into fully mature beta cells in an in vivo environment . Preparations are underway to carry out human trials using planar macrodevices modelled after the much-studied TheraCyte device , with the expectation that the membrane will protect the cells from the immune system and contain potentially dangerous cells, such as those capable of forming teratomas. Because of potential dangers, the macrodevices should be easily retrievable, which makes the subcutaneous site the most obvious possibility.
How much islet tissue can be supported by a given surface area that receives oxygen from the vasculature of surrounding tissue? Experience suggests that there will only be enough oxygen to support about 1,000 islet equivalent (IEQ)/cm2, with an IEQ defined as a standardised islet with a diameter of 150 μm . If a recipient requires 200,000 IEQ, then 400 cm2 of surface would be required, which would mean a sheet of 20 × 20 cm. This might be achieved with several smaller devices, but finding a surgical site to accommodate such a surface area will prove challenging. The situation could be improved if ways can be found to provide more oxygen by better vascularisation or other oxygen delivery approaches. This is less of a problem for microcapsules in the peritoneal cavity, but should remain a concern, particularly when capsules are large (diameter of 1,000 μm or more).
The concept that transplanted islet cells can be protected from immune destruction by a biomaterial barrier remains an attractive therapeutic approach in spite of the challenges being faced. In spite of these difficulties, the fact that this could lead to a major therapeutic advance, that many are now working on the problem, that progress is occurring, and that new concepts continue to emerge, justifies the renewed interest and support for intense investigation into the potential of this technology.
Duality of interest
The author holds stock options of the company Beta-O2 Technologies Limited.
The author conceived, drafted, wrote and approved this commentary.